Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06284213 · ClinicalTrials.gov registry record
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
A clinical trial of Dementia and Cognitive Impairment, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 1,892
- Enrollment target
- 17
- Study locations
NCT06284213: Active study of Dementia and Cognitive Impairment, sponsored by Massachusetts General Hospital.
NCT06284213 is a study of Dementia and Cognitive Impairment that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,892 participants, below the 7,713-participant average among 199 other Dementia trials with a reported enrollment target (75% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06284213, a study of Dementia and Cognitive Impairment, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 1,892 participants
- Enrollment target
- 17
- Study locations
Study Summary
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
Primary Outcome
Global cognition scores will be calculated at each study timepoint as an average of age- and education-specific z-scores, based on tests scores from the MarkVCID2 cognitive battery (MoCA, Neuropsychological Testing Battery, Clinical Dementia Rating), which is based on Version 3 of the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS) (Besser 2018).
Conditions Studied
Interventions
- OTHER No interventions
Study Locations (17)
California
- University of Southern California - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California Davis - Sacramento
- University of California San Francisco - San Francisco
- Olive View - UCLA Medical Center - Sylmar
Texas
- University of Texas Southwestern - Dallas
- University of Texas Health Science Center Houston - Houston
- University of Texas Health Science Center San Antonio - San Antonio
Maryland
- University of Maryland, Baltimore - Baltimore
- Johns Hopkins University - Baltimore
Florida
- Mayo Clinic Florida - Jacksonville
Illinois
- Rush University Medical Center & Illinois Institute of Technology - Chicago
Kentucky
- University of Kentucky - Lexington
Minnesota
- Mayo Clinic Rochester - Rochester
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,892 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2027-07 |
What the registry record for NCT06284213 still lists
NCT06284213 is an observational study that tracks outcomes without assigning an intervention. Its 1,892 participants enrollment target places it among the larger protocols in the corpus, below the 7,713-participant average among 199 other Dementia trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which No interventions is the first listed.
NCT06284213 lists 17 locations in 10 states (California, Texas, Maryland).
Frequently Asked Questions
What is clinical trial NCT06284213 about?
NCT06284213 is a clinical study titled "Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium". Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called bioma...
What is the current status of trial NCT06284213?
This trial is currently active not recruiting. The enrollment target is 1,892 participants. The study started on 2021-09-29. Estimated completion is 2027-07.
What conditions does trial NCT06284213 study?
This clinical trial studies the following conditions: Dementia, Cognitive Impairment.
What interventions are being tested in trial NCT06284213?
The interventions under investigation include: No interventions (OTHER).
Who is sponsoring clinical trial NCT06284213?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06284213 being conducted?
This trial has 17 study locations across California, Florida, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06284213's enrollment target sits among peer trials
1,892 27th of 199 higher than 173 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI